FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136175338> ?p ?o ?g. }

• W3136175338 endingPage "291" @default.
• W3136175338 startingPage "284" @default.
• W3136175338 abstract "•In a prospective large cohort of middle-aged Americans living in Texas, the prevalence of NAFLD was estimated to be 38%. •Based on liver histology data, NASH was diagnosed in 14% of the entire cohort and 37% of those with NAFLD. •NASH was more common in Hispanics and those with obesity or type 2 diabetes. Background & Aims Large prospective studies to establish the prevalence of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), are lacking. We prospectively assessed the prevalence and severity of NAFLD/NASH in a cohort of asymptomatic middle-aged Americans attending a colonoscopy class at a gastroenterology clinic. Methods Screening for NAFLD was performed using magnetic resonance (MR)-based LiverMultiScan® proton density fat fraction (LMS-PDFF). MR exams also included corrected T1 and elastography for liver stiffness measurement (LSM). FibroScan® was also used to measure LSM. Participants with predetermined abnormal imaging parameters were offered a liver biopsy. Biopsies were read in a blinded fashion with results based on the consensus by 2 expert pathologists. The prevalence of NAFLD was determined by PDFF ≥5% or by histological diagnosis of NAFLD (if biopsy data were available). The prevalence of NASH was defined by biopsy. Results Of 835 participants, 664 met the inclusion and exclusion criteria. The mean age was 56 ± 6.4 years, 50% were male, the mean BMI was 30.48 ± 5.46 kg/m2, and 52% were obese. The prevalence of NAFLD was 38% (95% CI 34–41%) and the prevalence of NASH was 14% (95% CI 12–17%). While no patient had cirrhosis on biopsy, significant fibrosis (F ≥2) was present in 5.9% (95% CI 4–8%) and bridging fibrosis in 1.6% (95% CI 1-3%). In a multivariable analysis, factors associated with the presence of NASH were race, obesity, and diabetes. Conclusion Using state-of-the-art liver imaging modalities and reference biopsy, this study establishes an overall prevalence of NAFLD of 38% and NASH by biopsy of 14% in this cohort of asymptomatic middle-aged US adults. Lay summary There are no prospective studies to determine how common is nonalcoholic steatohepatitis (NASH), the severe form of non-alcoholic fatty liver disease (NAFLD). In a large number of asymptomatic middle-aged Americans, we used a combination of state-of-the-art liver imaging methods and liver biopsy to prospectively determine the prevalence of NAFLD and NASH. NAFLD was diagnosed in 38%, NASH in 14%, and significant liver fibrosis in 6% of asymptomatic middle-aged Americans. Large prospective studies to establish the prevalence of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), are lacking. We prospectively assessed the prevalence and severity of NAFLD/NASH in a cohort of asymptomatic middle-aged Americans attending a colonoscopy class at a gastroenterology clinic. Screening for NAFLD was performed using magnetic resonance (MR)-based LiverMultiScan® proton density fat fraction (LMS-PDFF). MR exams also included corrected T1 and elastography for liver stiffness measurement (LSM). FibroScan® was also used to measure LSM. Participants with predetermined abnormal imaging parameters were offered a liver biopsy. Biopsies were read in a blinded fashion with results based on the consensus by 2 expert pathologists. The prevalence of NAFLD was determined by PDFF ≥5% or by histological diagnosis of NAFLD (if biopsy data were available). The prevalence of NASH was defined by biopsy. Of 835 participants, 664 met the inclusion and exclusion criteria. The mean age was 56 ± 6.4 years, 50% were male, the mean BMI was 30.48 ± 5.46 kg/m2, and 52% were obese. The prevalence of NAFLD was 38% (95% CI 34–41%) and the prevalence of NASH was 14% (95% CI 12–17%). While no patient had cirrhosis on biopsy, significant fibrosis (F ≥2) was present in 5.9% (95% CI 4–8%) and bridging fibrosis in 1.6% (95% CI 1-3%). In a multivariable analysis, factors associated with the presence of NASH were race, obesity, and diabetes. Using state-of-the-art liver imaging modalities and reference biopsy, this study establishes an overall prevalence of NAFLD of 38% and NASH by biopsy of 14% in this cohort of asymptomatic middle-aged US adults." @default.
• W3136175338 created "2021-03-29" @default.
• W3136175338 creator A5009096949 @default.
• W3136175338 creator A5019562801 @default.
• W3136175338 creator A5028469248 @default.
• W3136175338 creator A5031238914 @default.
• W3136175338 creator A5036463439 @default.
• W3136175338 creator A5038609111 @default.
• W3136175338 creator A5048710140 @default.
• W3136175338 creator A5053405300 @default.
• W3136175338 creator A5059781496 @default.
• W3136175338 creator A5060316115 @default.
• W3136175338 creator A5061616149 @default.
• W3136175338 creator A5075647936 @default.
• W3136175338 creator A5076713788 @default.
• W3136175338 creator A5082654129 @default.
• W3136175338 creator A5091625375 @default.
• W3136175338 date "2021-08-01" @default.
• W3136175338 modified "2023-10-16" @default.
• W3136175338 title "Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort" @default.
• W3136175338 cites W1622799587 @default.
• W3136175338 cites W1952814383 @default.
• W3136175338 cites W1963682935 @default.
• W3136175338 cites W1982702940 @default.
• W3136175338 cites W1983181715 @default.
• W3136175338 cites W1987934823 @default.
• W3136175338 cites W2003756626 @default.
• W3136175338 cites W2006560627 @default.
• W3136175338 cites W2010571737 @default.
• W3136175338 cites W2022296797 @default.
• W3136175338 cites W2049764675 @default.
• W3136175338 cites W2051919006 @default.
• W3136175338 cites W2059251195 @default.
• W3136175338 cites W2063976787 @default.
• W3136175338 cites W2067740038 @default.
• W3136175338 cites W2076858432 @default.
• W3136175338 cites W2089535377 @default.
• W3136175338 cites W2093904708 @default.
• W3136175338 cites W2095205890 @default.
• W3136175338 cites W2098555833 @default.
• W3136175338 cites W2116460737 @default.
• W3136175338 cites W2139654088 @default.
• W3136175338 cites W2201457922 @default.
• W3136175338 cites W2204688218 @default.
• W3136175338 cites W2299258372 @default.
• W3136175338 cites W2411583672 @default.
• W3136175338 cites W2534481205 @default.
• W3136175338 cites W2587779395 @default.
• W3136175338 cites W2743667261 @default.
• W3136175338 cites W2759630103 @default.
• W3136175338 cites W2767268548 @default.
• W3136175338 cites W2791708447 @default.
• W3136175338 cites W2793865429 @default.
• W3136175338 cites W2800368679 @default.
• W3136175338 cites W2891522467 @default.
• W3136175338 cites W2972561856 @default.
• W3136175338 cites W2993083975 @default.
• W3136175338 cites W3004467589 @default.
• W3136175338 cites W4293860580 @default.
• W3136175338 doi "https://doi.org/10.1016/j.jhep.2021.02.034" @default.
• W3136175338 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33746083" @default.
• W3136175338 hasPublicationYear "2021" @default.
• W3136175338 type Work @default.
• W3136175338 sameAs 3136175338 @default.
• W3136175338 citedByCount "98" @default.
• W3136175338 countsByYear W31361753382021 @default.
• W3136175338 countsByYear W31361753382022 @default.
• W3136175338 countsByYear W31361753382023 @default.
• W3136175338 crossrefType "journal-article" @default.
• W3136175338 hasAuthorship W3136175338A5009096949 @default.
• W3136175338 hasAuthorship W3136175338A5019562801 @default.
• W3136175338 hasAuthorship W3136175338A5028469248 @default.
• W3136175338 hasAuthorship W3136175338A5031238914 @default.
• W3136175338 hasAuthorship W3136175338A5036463439 @default.
• W3136175338 hasAuthorship W3136175338A5038609111 @default.
• W3136175338 hasAuthorship W3136175338A5048710140 @default.
• W3136175338 hasAuthorship W3136175338A5053405300 @default.
• W3136175338 hasAuthorship W3136175338A5059781496 @default.
• W3136175338 hasAuthorship W3136175338A5060316115 @default.
• W3136175338 hasAuthorship W3136175338A5061616149 @default.
• W3136175338 hasAuthorship W3136175338A5075647936 @default.
• W3136175338 hasAuthorship W3136175338A5076713788 @default.
• W3136175338 hasAuthorship W3136175338A5082654129 @default.
• W3136175338 hasAuthorship W3136175338A5091625375 @default.
• W3136175338 hasConcept C126322002 @default.
• W3136175338 hasConcept C188816634 @default.
• W3136175338 hasConcept C2775934546 @default.
• W3136175338 hasConcept C2777075537 @default.
• W3136175338 hasConcept C2777766500 @default.
• W3136175338 hasConcept C2777910003 @default.
• W3136175338 hasConcept C2778772119 @default.
• W3136175338 hasConcept C2779134260 @default.
• W3136175338 hasConcept C2779478299 @default.
• W3136175338 hasConcept C71924100 @default.
• W3136175338 hasConcept C72563966 @default.
• W3136175338 hasConcept C90924648 @default.
• W3136175338 hasConceptScore W3136175338C126322002 @default.
• W3136175338 hasConceptScore W3136175338C188816634 @default.

• next